Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.53 |
| ▸ | HTR2A | P28223 | 15/20 | 0.53 |
| ▸ | HTR2B | P41595 | 14/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079607 | 0.81 | HTR2C (0.46) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Bromide SCHEMBL2081894 | 0.79 | HTR2C (0.45) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL2080223 | 0.78 | HTR2C (0.51) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL13671841 | 0.77 | CHRNB2 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL31569405 | 0.77 | CHRNB2 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL12891724 | 0.75 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL12891722 | 0.75 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL2077267 | 0.74 | HTR2A (0.51) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL2077141 | 0.74 | HTR2C (0.49) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL2078314 | 0.74 | HTR2C (0.41) | HTR2CHTR2AHTR2BADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | claimed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | claimed |
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | disclosed |
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | disclosed |
| US-7897595-B2 | Pyridoazepine derivatives | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-03-01 | — | — | US | disclosed |
| WO-2007140213-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | disclosed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | disclosed |
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281918-A1 | PYRIDOAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.